Syndecan 2 (SDC2) antibody
| Antigen |
|
| Synonyms |
HSPG, HSPG1, SYND2, Hspg1, Synd2, AA960457, syndecan-2, 4833414L08Rik, cb440, zgc:103676 |
| Clonality |
Monoclonal (1F10-B8) |
|
Host
|
|
|
Reactivity
|
|
|
Application
|
 Alternatives Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA), Western Blotting (WB)
|
| Catalog no. |
ABIN191911 |
| Quantity |
10 µg (Variants) |
| Price |
215.00 $ Plus shipping costs $35.00
|
| Shipping to |
|
| Availability |
Ships within 7 to 10 Business Days |
|
Characteristics
|
Synonyms: SYND2, Fibroglycan, SDC2, small Heparan sulfate proteoglycan core protein
|
|
Alternative name
|
HSPG1 / Syndecan-2
|
|
Gene ID
|
6383
|
|
Swiss-Prot
|
P34741
|
|
Immunogen
|
Purified human small basement membrane heparan sulfate proteoglycan (HS-PG)
|
|
Cross-Reactivity
|
Human
|
|
Isotype
|
IgG1 (Matching secondary antibodies)
|
|
Clone
|
1F10-B8
|
|
Description
|
The principal molecular structure of basement membranes has been elucidated during thepast two decades and it was shown that for example in the glomerular basementmembrane (GBM) HS-PG are responsible for the selective filtration process. Removal ofHS-PG will lead to proteinuria. Whereas previously perlecan was the only known basementmembrane HS-PG, there is now evidence that (at least two) other basement membraneHS-PG do exist: Agrin, originally discovered as an important component of theneuromuscular junction and a novel small HS-PG, that was isolated from human aorta andkidney. This HS-PG, with a molecular weight of 80-200 kDa (aorta) and 30-160 kDa (kidney)and a core protein size of 24 kDa or 22 kDa, respectively, was localized byimmunohisto-chemistry to the basement membrane. Amino acid sequence analysis oftryptic peptides indicate, that this small HS-PG is clearly distinct from perlecan and agrin.
|
|
Specificity
|
Monoclonal Ab 1F10/B8 is specific for a core protein epitope of a human small basementmembrane heparan sulfate proteo-glycan (HS-PG). MAb 1F10/B8 recognizes an epitopedifferent from that recognized by mAb 2H7/G11 and mAb 2E2/B5. Species: Human. Others not tested.
|
|
Protocol
|
1. Stöcker G, Meyer HE, Wagener C and Greiling H (1991): Purification and N-terminal aminoacid sequence of a chondroitin sulfate / dermatan sulfate proteoglycan isolated fromintima / media preparations of human aorta. Biochem J 274: 415-420. 2. Heintz B, Stöcker G, Rentz U, Melzer H, Mrowka C, Stickeler E, Sieberth HG, Greiling H,Haubeck HD (1995): Decreased glomerular basement membrane heparan sulfateproteoglycan in essential hypertension. Hypertension 25: 399-407. 3. Stefanidis I, Heintz B, Stöcker G, Mrowka C, Sieberth HG, Haubeck HD (1996): Association between heparan sulfate proteoglycan excretion and proteinuria after renaltransplantation. J Am Soc Nephrol 7: 1-7. 4. Stöcker G, Stickeler E, Switalla S, Fischer DC, Greiling H, Haubeck HD (1997): Development of an enzyme immuno assay specific for a core protein epitope of a novelsmall basement membrane associated heparan sulphate proteoglycan from humankidney. Eur J Clin Chem Clin Biochem 35: 95-99.
|
|
Application Notes
|
ELISA (less than 1 ug/ml). Western blot (1 ug/ml). Immunohistochemistry (1 ug/ml). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
|
|
Purification
|
Purified
|
|
Buffer
|
50 mM TRIS pH 7,4Reconstitution: Restore in aqua bidest to 1 mg/ml.
|
|
Storage
|
Store lyophilized at 2 - 8 °C and reconstituted at -20 °C. Avoid repeated freezing andthawing. Shelf life: One year from despatch.
|
|
Restrictions
|
For Research Use only
|
Alternatives for antigen "Syndecan 2 (SDC2)", type "Antibodies"
